Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.74 |
| ▸ | CDK1 | P06493 | 7/20 | 0.59 |
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11346820 | 0.86 | IGF1R (1.00) | IGF1REGFRSYK | |
| SCHEMBL11346075 | 0.85 | IGF1R (1.00) | IGF1REGFRSYK | |
| SCHEMBL3270189 | 0.81 | IGF1R (0.72) | IGF1RCDK1KDRCDK19ALK | |
| SCHEMBL13898463 | 0.81 | IGF1R (0.54) | IGF1RCDK1KDRCDK19ALK | |
| SCHEMBL13898366 | 0.79 | IGF1R (0.52) | IGF1RCDK1KDRCDK2CCNB1 | |
| SCHEMBL4459525 | 0.79 | IGF1R (1.00) | IGF1RCDK1KDRCDK19ALK | |
| SCHEMBL3270958 | 0.78 | IGF1R (0.76) | IGF1RCDK1KDRCDK19ALK | |
| SCHEMBL13898422 | 0.78 | NUAK1 (0.57) | IGF1RCDK1KDRCDK2CCNB1 | |
| SCHEMBL7236862 | 0.78 | GSK3B (0.68) | IGF1RCDK1KDRCDK19ALK | |
| SCHEMBL13898290 | 0.78 | IGF1R (0.57) | IGF1RCDK1KDRCDK2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | IGF1R 967/4885CDK1 3/4885KDR 520/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | IGF1R 1072/4885CDK1 4/4885KDR 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.